INTRODUCTION: The patients with prostate cancer and low-volume osseous metastases who underwent local definitive therapies had lower risks of cancer-specific mortality. The usefulness of local definitive therapy for metastatic prostate cancer remains unclear. CASE PRESENTATION: A 76-year-old man visited a private hospital with a chief complaint of left lower limb pain. His serum prostate-specific antigen level was 365.156 ng/mL. Histological evaluation led to the initial diagnosis of adenocarcinoma of Gleason score 4 + 4 and clinical stage T3a N1 M1b. Although androgen deprivation therapy was performed, he developed metastatic castration-resistant prostate cancer 6 months after the initial treatment. Therefore, he received enzalutamide and attained a serum prostate-specific antigen level of 0.002 ng/mL 7 months after the second treatment. We performed robot-assisted radical prostatectomy 1 year after diagnosis. Histopathological examination revealed that prostate cancer cells disappeared into the prostate. CONCLUSION: Robot-assisted radical prostatectomy in selected patients with metastatic castration-resistant prostate cancer may improve oncological outcomes.
INTRODUCTION: The patients with prostate cancer and low-volume osseous metastases who underwent local definitive therapies had lower risks of cancer-specific mortality. The usefulness of local definitive therapy for metastatic prostate cancer remains unclear. CASE PRESENTATION: A 76-year-old man visited a private hospital with a chief complaint of left lower limb pain. His serum prostate-specific antigen level was 365.156 ng/mL. Histological evaluation led to the initial diagnosis of adenocarcinoma of Gleason score 4 + 4 and clinical stage T3a N1 M1b. Although androgen deprivation therapy was performed, he developed metastatic castration-resistant prostate cancer 6 months after the initial treatment. Therefore, he received enzalutamide and attained a serum prostate-specific antigen level of 0.002 ng/mL 7 months after the second treatment. We performed robot-assisted radical prostatectomy 1 year after diagnosis. Histopathological examination revealed that prostate cancer cells disappeared into the prostate. CONCLUSION: Robot-assisted radical prostatectomy in selected patients with metastatic castration-resistant prostate cancer may improve oncological outcomes.
Authors: Chad A Reichard; Justin R Gregg; Mary F Achim; Ana M Aparicio; Curtis A Pettaway; Louis L Pisters; John F Ward; John W Davis; Brian F Chapin Journal: Eur Urol Date: 2018-04-12 Impact factor: 20.096
Authors: Prasanna Sooriakumaran; Jeffrey Karnes; Christian Stief; Bethan Copsey; Francesco Montorsi; Peter Hammerer; Burkhard Beyer; Marco Moschini; Christian Gratzke; Thomas Steuber; Nazareno Suardi; Alberto Briganti; Lukas Manka; Tommy Nyberg; Susan J Dutton; Peter Wiklund; Markus Graefen Journal: Eur Urol Date: 2015-05-30 Impact factor: 20.096
Authors: Thomas Steuber; Kasper D Berg; Martin A Røder; Klaus Brasso; Peter Iversen; Hartwig Huland; Anne Tiebel; Thorsten Schlomm; Alexander Haese; Georg Salomon; Lars Budäus; Derya Tilki; Hans Heinzer; Markus Graefen; Philipp Mandel Journal: Eur Urol Focus Date: 2017-07-08
Authors: Axel Heidenreich; Nicola Fossati; David Pfister; Nazareno Suardi; Francesco Montorsi; Shahrokh Shariat; Bernhard Grubmüller; Giorgio Gandaglia; Alberto Briganti; R Jeffrey Karnes Journal: Eur Urol Oncol Date: 2018-05-15
Authors: Jeffrey J Tosoian; Michael A Gorin; Ashley E Ross; Kenneth J Pienta; Phuoc T Tran; Edward M Schaeffer Journal: Nat Rev Urol Date: 2016-10-11 Impact factor: 14.432
Authors: Axel Heidenreich; Patrick J Bastian; Joaquim Bellmunt; Michel Bolla; Steven Joniau; Theodor van der Kwast; Malcolm Mason; Vsevolod Matveev; Thomas Wiegel; Filiberto Zattoni; Nicolas Mottet Journal: Eur Urol Date: 2013-11-12 Impact factor: 20.096